📊 ENGNW Key Takeaways
Is enGene Holdings Inc. (ENGNW) a Good Investment?
enGene Holdings is a pre-revenue biotech company with significant cash burn, negative operating income of -$31.2M and negative free cash flow of -$29.1M, indicating it is not yet commercially viable. While the company maintains adequate liquidity with $36.6M in cash and a strong balance sheet with minimal debt, the burn rate suggests limited runway without additional capital raises or achieving clinical milestones.
enGene Holdings appears to be a pre-revenue or very early commercial-stage biotech with no reported revenue, deeply negative operating cash flow, and continued operating losses, which makes current fundamentals weak on profitability and self-funding capacity. The main offset is an unusually strong balance sheet, with high liquidity, no meaningful debt, and substantial equity capital, but the business still depends on clinical/commercial execution before its financial profile can materially improve.
Why Buy enGene Holdings Inc. Stock? ENGNW Key Strengths
- Strong balance sheet with $281.5M stockholders' equity and minimal debt (0.00x debt/equity ratio)
- Adequate liquidity position with $36.6M cash and 11.75x current ratio providing runway for operations
- Biological products sector with potential for high-value therapeutic development
- Very strong liquidity with current and quick ratios of 11.75x
- Debt-free balance sheet with $281.55M in equity and 0.00x debt/equity
- Large asset base relative to liabilities provides near-term financial flexibility
ENGNW Stock Risks: enGene Holdings Inc. Investment Risks
- Pre-revenue stage with negative operating income of -$31.2M and negative free cash flow of -$29.1M indicating ongoing cash burn
- Lack of revenue generation suggests clinical programs have not yet achieved commercialization or FDA approval
- Annual cash burn of ~$29M against current cash balance suggests less than 2 years of runway without dilutive financing
- Negative ROE of -10.6% and ROA of -8.8% reflect value destruction for shareholders
- No reported revenue or gross profit makes growth quality and commercial traction unproven
- Operating loss of $31.18M and free cash flow of -$29.06M indicate ongoing cash burn
- Reported positive diluted EPS despite net loss suggests accounting complexity or data inconsistency that investors should scrutinize
Key Metrics to Watch
- Cash burn rate and runway to profitability or next inflection point
- Clinical trial progress and regulatory milestones for pipeline candidates
- Path to revenue generation and proof of commercial viability
- Quarterly cash burn versus cash and equivalents
- Revenue emergence and operating loss trend
enGene Holdings Inc. (ENGNW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 11.75x current ratio provides a solid financial cushion.
ENGNW Profit Margin, ROE & Profitability Analysis
ENGNW vs Healthcare Sector: How enGene Holdings Inc. Compares
How enGene Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is enGene Holdings Inc. Stock Overvalued? ENGNW Valuation Analysis 2026
Based on fundamental analysis, enGene Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
enGene Holdings Inc. Balance Sheet: ENGNW Debt, Cash & Liquidity
ENGNW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: enGene Holdings Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.46 reflects profitable operations.
ENGNW Revenue Growth, EPS Growth & YoY Performance
enGene Holdings Inc. Dividends, Buybacks & Capital Allocation
ENGNW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for enGene Holdings Inc. (CIK: 0001980845)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENGNW
What is the AI rating for ENGNW?
enGene Holdings Inc. (ENGNW) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENGNW's key strengths?
Claude: Strong balance sheet with $281.5M stockholders' equity and minimal debt (0.00x debt/equity ratio). Adequate liquidity position with $36.6M cash and 11.75x current ratio providing runway for operations. ChatGPT: Very strong liquidity with current and quick ratios of 11.75x. Debt-free balance sheet with $281.55M in equity and 0.00x debt/equity.
What are the risks of investing in ENGNW?
Claude: Pre-revenue stage with negative operating income of -$31.2M and negative free cash flow of -$29.1M indicating ongoing cash burn. Lack of revenue generation suggests clinical programs have not yet achieved commercialization or FDA approval. ChatGPT: No reported revenue or gross profit makes growth quality and commercial traction unproven. Operating loss of $31.18M and free cash flow of -$29.06M indicate ongoing cash burn.
What is ENGNW's revenue and growth?
enGene Holdings Inc. reported revenue of N/A.
Does ENGNW pay dividends?
enGene Holdings Inc. does not currently pay dividends.
Where can I find ENGNW SEC filings?
Official SEC filings for enGene Holdings Inc. (CIK: 0001980845) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENGNW's EPS?
enGene Holdings Inc. has a diluted EPS of $0.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENGNW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, enGene Holdings Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENGNW stock overvalued or undervalued?
Valuation metrics for ENGNW: ROE of -10.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENGNW stock in 2026?
Our dual AI analysis gives enGene Holdings Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENGNW's free cash flow?
enGene Holdings Inc.'s operating cash flow is $-28.9M, with capital expenditures of $153.0K.
How does ENGNW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -10.6% (avg: 15%), current ratio 11.75 (avg: 2).